Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-8.57%+58.09%+124.47% 54.63B
-5.60%-2.20%+11.16%+437.37% 25.06B
-1.55%-7.66%-20.21%-17.37% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+1.87%+38.13%-26.14% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.81%+0.34%+24.92%+189.31% 14.2B
Average -1.60%-0.82%+49.26%+198.28% 26.84B
Weighted average by Cap. -1.81%-1.56%+48.50%+166.90%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-